Lek’s TechBEAT receives the 2024 Engineering Spark award
- The Engineering Spark awards were presented for the fifth year in a row by the “We Will Be Engineers!” initiative.
- Lek is the recipient of the award for TechBEAT – an event for promising secondary school students of science and engineering, organized for the first time this year.
- The award is a reflection of Lek's culture, which prioritizes talent management, as well as development and long-term support of promising students.
Lek, a Sandoz company, is the recipient of the 2024 Engineering Spark award for its TechBEAT event. The award, presented by the “We Will Be Engineers!” initiative, recognizes groundbreaking practices and projects that have an important contribution to the development, reputation and enthusiasm for the engineering profession and innovation in society.
“At Lek, we actively promote the development of critical thinking, innovation and entrepreneurship at all levels of the education system, working with schools and academic institutions to create a more knowledge-based and connected society. We will continue to seek and support emerging professionals and co-create an environment where every individual can contribute to societal innovation, progress and wellbeing,” said Robert Ljoljo, President of the Lek Board of Management and Sandoz Country President Slovenia and added:
| “I am happy that our efforts have been recognized and also incredibly proud of our associates, whose innovative approaches open the door of the pharmaceutical industry to promising students.” | Robert Ljoljo, President of the Lek Board of Management |
Between May 9 and 10 in Ljubljana and Bled, TechBEAT brought together thirty participants from seven Slovenian secondary schools, offering them a unique insight into the challenges and trends in the pharmaceutical industry, an opportunity to network, gain concrete knowledge and experience, and get a professional insight into state-of-the-art technology. The event received positive feedback from participants and their mentors alike; the latter highlighted the importance of collaboration between educational institutions and businesses, as well as the transfer of knowledge across generations.
Lek recognizes the importance of taking on employment challenges strategically and proactively; a close-knit collaboration between companies and the wider educational and business communities should not be underestimated. The company thus takes an innovative approach to acquiring emerging and established professionals, which is reflected in numerous accolades for their P&O practices and projects. One such example is ScienceBEAT – an event bringing together emerging science and business professionals and industry-leading scientists, researchers, and entrepreneurs.
Other recipients of the Engineering Spark award were the Jurija Vega Gymnasium for their FPV drone and the Elementary School Breg from Ptuj for mentoring young people.
About Lek
Lek, a Sandoz company, is the first and oldest pharmaceutical company in Slovenia, developing, manufacturing and marketing effective, safe and high-quality generics and biosimilars for patients around the world. Our work is guided by strong ethical standards, innovative thinking and the breakthrough achievements of our world-class professionals. With more than 3,700 associates, we have been actively shaping the Slovenian, European and global research and development landscape for decades. We are building a culture of open dialog, and we proudly and responsibly hold the title of most reputable employer in Slovenia.
About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the first biosimilar in 2006. In 2023, Sandoz recorded sales of USD 9.6 billion.
Disclaimer
This Media Release contains forward-looking statements which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
Photo for print
Previous press releases
Contact us
Gregor Makuc
T: +386 1 580 22 43
info.lek@sandoz.com